

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/622,108	ATTY. DOCKET NO.: S1383.70011US00
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		FILING DATE: July 17, 2003	CONFIRMATION NO.: 5945
		APPLICANT: Blumberg et al.	
Sheet	1	of	3
		GROUP ART UNIT: 1614	EXAMINER: Unknown

### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
RS	A1	4,678,751		Goeddel	07-07-1987
	A2	4,695,623		Stabinsky	11-22-1987
	A3	4,801,685		Goeddel et al.	01-31-1989
	A4	4,820,638		Swetly et al.	04-11-1989
	A5	4,897,471		Stabinsky	01-30-1990
	A6	4,921,699		DeChiara et al.	05-01-1990
	A7	4,973,479		Innis	11-27-1990
	A8	4,975,276		Innis	12-04-1990
	A9	5,098,703		Innis	03-24-1992
	A10	5,290,540		Prince et al.	03-01-1994
	A11	5,310,729		Lernhardt	05-10-1994
	A12	5,372,808		Blatt et al.	12-13-1994
	A13	5,541,293		Stabinsky	06-30-1996
	A14	5,605,690		Jacobs et al.	02-25-1997
	A15	5,661,009		Stabinsky	08-26-1997
	A16	5,723,125		Chang et al.	03-03-1998
	A17	5,758,637		Ivri et al.	06-02-1998
	A18	5,824,307		Johnson	10-20-1998
	A19	5,869,293		Pestka	02-09-1999
	A20	5,874,064		Edwards et al.	02-23-1999
	A21	5,938,117		Ivri	08-17-1999
	A22	5,980,884		Blatt et al.	11-09-1999
	A23	6,014,970		Ivri et al.	01-18-2000
	A24	6,019,968		Platz et al.	02-01-2000
	A25	6,030,613		Blumberg et al.	02-29-2000
	A26	6,085,740		Ivri et al.	07-11-2000
	A27	6,086,875		Blumberg et al.	07-11-2000
	A28	6,165,463		Platz et al.	12-26-2000
	A29	6,205,999	B1	Ivri et al.	03-27-2001
	A30	6,300,474	B1	Pestka	10-09-2001
	A31	6,423,344	B1	Platz et al.	07-23-2002
	A32	6,485,726	B1	Blumberg et al.	11-26-2002

### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
RS	B1	WO	91/03553	A1	Immunex Corp.	03-21-1991	

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/622,108		ATTY. DOCKET NO.: S1383.70011US00	
				FILING DATE: July 17, 2003		CONFIRMATION NO.: 5945	
				APPLICANT: Blumberg et al.			
				GROUP ART UNIT: 1614		EXAMINER: Unknown	
Sheet	2	of	3				

**FOREIGN PATENT DOCUMENTS (continued)**

B2	WO	91/16074	A1	Medimmune, Inc.	10-31-1991
B3	WO	94/06476	A1	Immunex Corp.	03-31-1994
B4	WO	96/22024	A1	The Brigham and Women's Hospital, Inc.	07-25-1996
B5	WO	00/69913	A1	Lexigen Pharmaceuticals Corp.	11-23-2000
B6	WO	01/03737	A1	Bolder Biotechnology, Inc.	01-18-2001
B7	WO	02/43660	A2	Medimmune, Inc.	06-06-2002
B8	WO	03/077834	A2	The Brigham and Women's Hospital, Inc.	09-25-2003

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PC	C1	AGNEW JE et al., Functional small airways defence in symptomless cigarette smokers. <i>Thorax</i> . 1986 Jul;41(7):524-30.	
	C2	BASELGA J et al., Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. <i>Cancer Res</i> . 1998 Jul 1;58(13):2825-31.	
	C3	BROWN AR et al., Chamber for testing metered-dose propellant-driven aerosols of immunologically relevant proteins. <i>J Immunol Methods</i> . 1994 Dec 2;176(2):203-12.	
	C4	BURMEISTER WP et al., Crystal structure of the complex of rat neonatal Fc receptor with Fc. <i>Nature</i> . 1994 Nov 24;372(6504):379-83.	
	C5	BYRON PR, Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. <i>J Pharm Sci</i> . 1986 May;75(5):433-8.	
	C6	FAHY JV et al., Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. <i>Am J Respir Crit Care Med</i> . 1999 Sep;160(3):1023-7.	
	C7	FLEMING JS et al., Evaluation of the accuracy and precision of lung aerosol deposition measurements from single-photon emission computed tomography using simulation. <i>J Aerosol Med</i> . 2000 Fall;13(3):187-98.	
	C8	FRIEND PJ et al., Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. <i>Transplantation</i> . 1999 Dec 15;68(11):1632-7.	
	C9	IMPACT-RSV STUDY GROUP, Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. <i>Pediatrics</i> . 1998 Sep;102(3 Pt 1):531-7.	
	C10	KNIGHT DM et al., Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. <i>Mol Immunol</i> . 1993 Nov;30(16):1443-53.	
	C11	LALOR CB et al., Generation and characterization of aerosols for drug delivery to the lungs. In: <i>Inhalation Delivery of Therapeutic Peptides and Proteins</i> , Adjei AL and Gupta PK, eds., New York: Marcel Dekker, 1997, pp 235-276.	
	C12	MARTIN WL et al., Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. <i>Mol Cell</i> . 2001 Apr;7(4):867-77.	
	C13	NEWMAN SP et al., Understanding regional lung deposition data in gamma scintigraphy. <i>Respiratory Drug Delivery</i> . 1998;VI:9-15.	
fs	C14	OBER RJ et al., Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. <i>Int Immunol</i> . 2001 Dec;13(12):1551-9.	

11/1/05

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/622,108	ATTY. DOCKET NO.: S1383.70011US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: July 17, 2003	CONFIRMATION NO.: 5945
		APPLICANT: Blumberg et al.	
Sheet	3	of	3
		GROUP ART UNIT: 1614	EXAMINER: Unknown

OTHER ART — NON PATENT LITERATURE DOCUMENTS (continued)


RS	C15	PIAZZA FM et al., Immunotherapy of respiratory syncytial virus infection in cotton rats ( <i>Sigmodon fulviventer</i> ) using IgG in a small-particle aerosol. <i>J Infect Dis.</i> 1992 Dec;166(6):1422-4.		
	C16	ROBINSON CR et al., Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1998 May; 95:5929-35.		
	C17	ROUTLEDGE EG et al., The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. <i>Transplantation.</i> 1995 Oct 27;60(8):847-53.		
	C18	SHIELDS RL et al., High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. <i>J Biol Chem.</i> 2001 Mar 2;276(9):6591-604. Epub 2000 Nov 28.		
	C19	STORY CM et al., A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. <i>J Exp Med.</i> 1994 Dec 1;180(6):2377-81.		
	C20	SWEENEY TD et al., Biopharmaceutics of immunoglobulin transport across lung epithelium. <i>Respiratory Drug Delivery.</i> 2000;VII:59-66.		
	C21	WEST AP et al., Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(.). <i>Biochemistry.</i> 2000 Aug 15;39(32):9698-708.		
RS	C22	YU J et al., Pulmonary drug delivery: physiologic and mechanistic aspects. <i>Crit Rev Ther Drug Carrier Syst.</i> 1997;14(4):395-453.		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			APPLICATION NO.: 10/622,108	ATTY. DOCKET NO.: S1383.70011US00	
			FILING DATE: July 17, 2003	CONFIRMATION NO.: 5945	
			APPLICANT: Blumberg et al.		
			GROUP ART UNIT: 1724	EXAMINER: unknown	
Sheet	1	of	1		

**U.S. PATENT DOCUMENTS**


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
PS	B9	WO	2004/004798	A3	The Brigham and Women's Hospital, Inc.	01-15-2004	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	

EXAMINER: 	DATE CONSIDERED: 11/10/05
---	---------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]